2007, 2008, 2009
In collaboration with an anonymous funder, Cure Alzheimer’s Fund is supporting development of a facility to measure the concentration of Amyloid-beta in real time in the brain of living, behaving mouse models that develop features of AD. The model enables screening for drugs that lower Amyloid-beta directly in the brain in relatively high throughput.
$278,238
Drug Discovery, Drug Screening Projects
David M. Holtzman, M.D.